Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 131-135

  Gandara, David R ^a   Vokes, Everett ^a   Green, Mark ^a   Bonomi, Phillip ^a   Devore, Russell ^a   Comis, Robert ^a   Carbone, David ^a   Karp, Daniel ^a   Belani, Chandra ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0033988085     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.131     Document Type: Article

References (27)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995
2. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
3. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
4. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small cell lung cancer. N Eng J Med 323:904-905, 1990
5. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
6. Resell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153-158, 1994
7. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable Stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86:673-680, 1994
8. Edelman MJ, Gandara DR: Promising new agents in the treatment of lung cancer. Cancer Chemother Pharmacol 37:385-393, 1996
9. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
10. Le Chevalier T, Brisgand D, Douillard J-Y, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
11. Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide cisplatin versus Taxol with cisplatin-G-CSF versus Taxol-cisplatin in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 15:382, 1996 (abstr 1145)
12. Sandler A, Nemunitis J, Dehnam C, et al: Phase III study of cisplatin with or without gemcitabine in patients with advanced NSCLC. Proc Am Soc Clin Oncol 17:454, 1998 (abstr 1747)
13. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
14. Burris H, Echardt J, Fields S, et al: Phase II trials of taxotere in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 12:A1116, 1993 (abstr 1212)
15. Pronzato P, Landucci M, Vaira F, et al: Failure of vinorelbine to produce responses in pretreated non-small-cell lung cancer. Anticancer Res 14:1413-1415, 1994
16. Rinaldi M, Della Gulia M, Ventura I, et al: Vinorelbine as single agent in the treatment of advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 12:360, 1994 (abstr 1212)
17. Furuse K, Ohta M, Fukuoka M, et al: Early phase II clinical study of KW2307 in patients with lung cancer: Lung cancer section in KW-2307 Study Group. Gan To Kagaku Ryoho 21:785-793, 1994
18. Ruckdeschel J, Wagner H, Williams C Jr, et al: Second-line chemotherapy for resistant, metastatic, non-small-cell lung cancer (NSCLC): The role of Taxol. Proc Am Soc Clin Oncol 13:357, 1994 (abstr 357)
19. Hainsworth JD, Thompson DA, Greco FA: Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13:1609-1614, 1995
20. Murphy WK, Winn RJ, Huber M, et al: Phase II study of Taxol (t) in patients (pt) with non-small-cell lung cancer (NSCLC) who have failed platinum (p) containing chemotherapy (ctx). Proc Am Soc Clin Oncol 13:363, 1994 (abstr 363)
21. Crino L, Mosconi AM, Scagliotti GV, et al: Gemcitabine as a second-line treatment for relapsing or refractory advanced non-small cell lung cancer: A phase II trial. Semin Oncol 25:23-26, 1998 (suppl 9)
22. Weinstein JN, Myers TG, O'Connor PM, et al: An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349, 1998
23. O'Connor PM, Jackman J, Bae I, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300, 1997
24. Gumerlock PH, Mack PC, Manorek GH, et al: Bcl2 phosphorylation and p27 induction as potential p53-independent mechanisms of apoptotic responses to taxanes in non-small cell lung carcinoma. Proc Am Assoc Cancer Res 40:730. 1999 (abstr 4879)
25. waf1 and p53 requires c-raf-1. Cancer Res 55:4623-4626, 1995
26. Gumerlock PH, Mack PC, Law SM, et al: Molecular mechanisms of response to cell cycle modulating agents in non-small cell lung carcinoma (NSCLC). Proc Am Assoc Cancer Res 39:610, 1998, (abstr 4152)
27. Haldar S, Chintapali J, Croce CM: Taxol Induces bcl-2 Phosphorylation and Death of Prostate Cancer Cells. Cancer Res 56:1253-1255, 1996.